LZ901, A Recombinant Herpes Zoster Vaccine And The Core Product Of Luzhu Biotechnology, Completed Phase II Clinical Trail In Q2 2023
- Written by PR Newswire
World's First Herpes Zoster Vaccine With A Tetrameric Molecular Structure
BEIJING, May 30, 2023 /PRNewswire/ -- Beijing Luzhu Biotechnology Co., Ltd. ("Luzhu Biotechnology" or the "Company", together with its subsidiaries, the "Group", stock code: 02480.HK), a leading vaccine and antibody drug developer in China, is pleased to announce that the...